Patents by Inventor Mart Ustav
Mart Ustav has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340542Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.Type: ApplicationFiled: May 10, 2023Publication date: October 26, 2023Inventors: Kadri ÕUNAP, Eva-Maria TOMBAK, Mart TOOTS, Madis JAKOBSON, Mart USTAV, Jr., Kerttu MURUMETS, Urve TOOTS, Andres MÄNNIK, Mart USTAV, Sr.
-
Patent number: 11685936Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.Type: GrantFiled: October 17, 2019Date of Patent: June 27, 2023Assignee: Icosagen Cell Factory OÜInventors: Kadri Õunap, Eva-Maria Tombak, Mart Toots, Madis Jakobson, Mart Ustav, Jr., Kerttu Murumets, Urve Toots, Andres Männik, Mart Ustav, Sr.
-
Patent number: 11000529Abstract: Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: GrantFiled: September 12, 2019Date of Patent: May 11, 2021Assignee: Icosagen Cell Factory OÜInventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
-
Patent number: 10995134Abstract: This invention provides a method and a kit for rapid and robust development monoclonal antibodies. The method does not require hybrid technologies nor does it require single cell manipulations. The method allows elimination of cross-target antibodies.Type: GrantFiled: September 30, 2016Date of Patent: May 4, 2021Assignee: Icosagen Cell Factoey OilInventors: Gaily Kivi, Kaupo Teesalu, Jüri Parik, Mart Ustav, Andres Männik
-
Patent number: 10954545Abstract: A U2OS-based model system using luciferase reporters to monitor the genome replication of alpha and beta HPVs is provided. A modified U2OS cell line is disclosed that expresses Firefly luciferase to measure toxicity of the screened compounds. In addition, provided are HPV18, HPV 16 and HPV5 marker genomes that express Renilla luciferase under the control of viral promoters used to measure changes in the viral copy number. This ready-to-use model system is capable of being used in high-throughput screens to identify compounds inhibiting initial amplification and stable maintenance as well as vegetative phase of various HPV subtypes.Type: GrantFiled: April 11, 2016Date of Patent: March 23, 2021Assignee: Icosagen Cell Factory OÜInventors: Mart Ustav, Ene Ustav, Andres Männik, Mart Toots, Mart Ustav, Jr., Andres Tover
-
Publication number: 20200123576Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.Type: ApplicationFiled: October 17, 2019Publication date: April 23, 2020Applicant: Icosagen Cell Factory OÜInventors: Kadri ÕUNAP, Eva-Maria TOMBAK, Mart TOOTS, Madis JAKOBSON, Mart USTAV, Jr., Kerttu MURUMETS, Urve TOOTS, Andres MÄNNIK, Mart USTAV, Sr.
-
Publication number: 20200046730Abstract: Methods for treating high risk HPV infection by inhibiting one or more phases of HPV replication cycle with antiviral compounds are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: ApplicationFiled: September 12, 2019Publication date: February 13, 2020Applicant: Icosagen Cell Factory OÜInventors: Mart USTAV, SR., Ene USTAV, Andres MÄNNIK, Mart TOOTS, Andres TOVER
-
Patent number: 10543218Abstract: Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: GrantFiled: May 11, 2016Date of Patent: January 28, 2020Assignee: Icosagen Cell Factory OÜInventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
-
Publication number: 20180273611Abstract: This invention provides a method and a kit for rapid and robust development monoclonal antibodies. The method does not require hybrid technologies nor does it require single cell manipulations. The method allows elimination of cross-target antibodies.Type: ApplicationFiled: September 30, 2016Publication date: September 27, 2018Applicant: Icosagen Cell Factory OÜInventors: Gaily KIVI, Kaupo TEESALU, Jüri PARIK, Mart USTAV, Andres MÄNNIK
-
Publication number: 20180155756Abstract: A U2OS-based model system using luciferase reporters to monitor the genome replication of alpha and beta HPVs is provided. A modified U2OS cell line is disclosed that expresses Firefly luciferase to measure toxicity of the screened compounds. In addition, provided are HPV18, HPV 16 and HPV5 marker genomes that express Renilla luciferase under the control of viral promoters used to measure changes in the viral copy number. This ready-to-use model system is capable of being used in high-throughput screens to identify compounds inhibiting initial amplification and stable maintenance as well as vegetative phase of various HPV subtypes.Type: ApplicationFiled: April 11, 2016Publication date: June 7, 2018Applicant: Icosagen Cell Factory OÜInventors: Mart USTAV, Ene USTAV, Andres MÄNNIK, Mart TOOTS, Mart USTAV, JR., Andres TOVER
-
Publication number: 20180133228Abstract: Novel antiviral compounds for inhibiting one or more phases of HPV replication cycle are disclosed. Moreover, a mechanism for the inhibition is suggested and targets for further antiviral compounds are disclosed.Type: ApplicationFiled: May 11, 2016Publication date: May 17, 2018Applicant: Icosagen Cell Factory OÜInventors: Mart Ustav, Sr., Ene Ustav, Andres Männik, Mart Toots, Andres Tover
-
Patent number: 9725486Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: GrantFiled: January 13, 2014Date of Patent: August 8, 2017Assignee: Fit Biotech OYInventors: Kai Krohn, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Patent number: 9474800Abstract: The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today.Type: GrantFiled: May 22, 2009Date of Patent: October 25, 2016Assignee: FIT Biotech OYInventors: Kaja Kiiver, Rein Sikut, Urve Toots, Tarmo Mölder, Andres Männik, Mart Ustav, Katrin Kaldma
-
Publication number: 20140234361Abstract: A method for treating an HIV disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a DNA vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a DNA sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a DNA binding domain which binds to a specific DNA binding sequence, and (ii) a functional domain of the Bovine Papilloma Virus Type 1 E2 protein, where the functional domain binds to a nuclear component; (b) a multimerized DNA sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a DNA sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.Type: ApplicationFiled: January 13, 2014Publication date: August 21, 2014Applicant: FIT Biotech OyInventors: Kai KROHN, Vesna Blazevic, Marja Tähtinen, Mart Ustav, Urve Toots, Andres Männik, Annamari Ranki, Ene Ustav
-
Publication number: 20130236958Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).Type: ApplicationFiled: January 23, 2013Publication date: September 12, 2013Applicant: ICOSAGEN CELL FACTORY OUInventors: Toomas SILLA, Ingrid TAGEN, Jelizaveta GEIMANEN, Kadri JANIKSON, Aare ABROI, Ene USTAV, Mart USTAV, Tiiu MANDEL, Urve TOOTS, Andres TOVER, Anne KALLING, Radi TEGOVA
-
Patent number: 8377653Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).Type: GrantFiled: July 7, 2010Date of Patent: February 19, 2013Assignee: Icosagen Cell Factory OüInventors: Toomas Silla, Ingrid Tagen, Anne Kalling, Radi Tegova, Mart Ustav, Tiiu Mandel, Urve Toots, Andres Tover, Aare Abroi, Ene Ustav, Jelizaveta Geimanen, Kadri Janikson
-
Publication number: 20110171255Abstract: The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today.Type: ApplicationFiled: May 22, 2009Publication date: July 14, 2011Applicant: Fit Biotech OyInventors: Kaja Kiiver, Rein Sikut, Urve Toots, Tarmo Mölder, Andres Männik, Mart Ustav, Katrin Kaldma
-
Publication number: 20110076760Abstract: This disclosure shows that the EBV FR-element comprised of EBNA1 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT).Type: ApplicationFiled: July 7, 2010Publication date: March 31, 2011Applicant: Icosagen S.A.Inventors: Toomas Silla, Ingrid Tagen, Anne Kalling, Radi Tegova, Mart Ustav, Tiiu Mandel, Urve Toots, Andres Tover, Aare Abroi, Ene Ustav, Jelizaveta Geimanen, Kadri Janikson
-
Publication number: 20100279416Abstract: The invention relates to a method for introducing changes into a eukaryotic genome in vivo wherein the HPV genome, which comprises HPV replication origin sequence, is used together with HPV early proteins in order to achieve DNA replication in vivo. There is also disclosed a kit for in vivo amplification, excision, translocation and/or inversion of a DNA sequence, which comprises a vector carrying HPV genome or a part of HPV genome including HPV replication origin sequence, and expression vector or vectors encoding HPV early proteins.Type: ApplicationFiled: March 27, 2008Publication date: November 4, 2010Inventors: Mart Ustav, Ene Ustav, Meelis Kadaja, Alina Sumerina
-
Patent number: 7790446Abstract: This disclosure shows that the BPV-1 E2 protein-dependent minichromosome maintenance element (MME) comprised of E2 multimeric binding sites can provide the stable maintenance replication function to the mouse polyomavirus (PyV) core origin plasmids in the presence of BPV-1 E2 protein and PyV large T-antigen (LT). MME dependent plasmids are lost with the frequency of 6% per generation. Significantly long stable maintenance replication can also be provided without selection pressure. We also demonstrate that PyV core origin maintenance function/replication activation could be provided by Epstein-Barr virus Family of repeats and EBNA1 protein. The maintenance of the Polyomavirus core origin plasmid was characterized by 13% loss of the plasmid during one cell generation in the case of EBV FR harboring plasmids.Type: GrantFiled: February 10, 2006Date of Patent: September 7, 2010Assignee: Kosagen Cell Factory OüInventors: Toomas Silla, Ingrid Tagen, Jelizaveta Geimanen, Kadri Janikson, Aare Abroi, Ene Ustav, Mart Ustav, Tiiu Mandel